International Journal of Clinical Science and Medical Research

The incidence of carbimazole-induced liver injury (DILI) in patients treated for hyperthyroidism is infrequent, ranging from 0.1% to 0.5%. Whilethe injury usuallyfollows a cholestatic pattern, the condition can also present with mixed or cytolytic features, driven by either immune-mediated responses or the metabolic involvement of cytochrome P450 enzymes.We report the case of a 29-year-old woman with Graves’ disease (free T4: 78 pmol/L) who developed severe hepatotoxicity two weeks after initiating 40 mg/dayof Carbimazole. The patient presented with clinical jaundice and laboratory findings of significant cholestasis. After excluding viral, autoimmune, and structural etiologies, a diagnosis of carbimazole-induced hepatotoxicity was established.

Management included immediate cessation of the antithyroid drug, initiation of corticosteroid therapy (1 mg/kg/day), and a session of plasmapheresis to bridge the patient safely toward a thyroidectomy. Liver function showed marked improvement within one week of discontinuation. These findings suggest that when conventional cessation of the drug is insufficient to stabilize rapidly deteriorating liver enzymes, advanced extracorporeal therapies may serve as a crucial bridge to definitive surgical intervention. Ultimately, this report reinforces the necessity of vigilantmonitoring of liverfunction tests during the initiation of carbimazole therapy. By advocating for proactive serial biochemical screening, we aim to standardize safer clinical practices and improve outcomes for patients requiring rapid definitive treatment in the setting of severe, unpredictable, and potentially life-threatening drug-induced liver injury caused by antithyroid medications.

Carbimazole, Drug-induced liver injury, Cytolytic hepatitis, Hyperthyroidism, Graves' disease

1. Ross, D. S., Burch,H. B., Cooper, D. S., et al. (2016). 2016 American ThyroidAssociation guidelines for diagnosis and management of hyperthyroidism. Thyroid, 26(10), 1343–1421.
2. Al Hariri,B., Elhassan, M. E. O., Alsidig, H. A. T., et al. (2025). Cholestatic hepaticinjury induced by carbimazole: A case reportand a thorough literature review.Clinical Case Reports,13, Article e70498.
3. Manzoor, R., Saeed, B., & Manzoor,M. (2014). Factorsaffecting drug-induced liver injury: Antithyroid drugs as instances. PMC.
4. Nakamura, H., Noh, J. Y., Itoh,K., et al. (2007). Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease. Journal of Clinical Endocrinology & Metabolism, 92(6), 2157–2162.
5. Li, J., Hussain, Z., Zhu, J., et al. (2021). Role of CYP2A6in methimazole bioactivation and hepatotoxicity. Chemical Research in Toxicology, 34(11), 2534–2539.
6. Morini, L., Turchetti, D., Cavani, S., et al. (2018). Hepatotoxicity in hyperthyroid patient after consecutive methimazole and propylthiouracil therapies. Endocrinology, Diabetes & Metabolism Case Reports, 2018, Article EDM17-0173.
7. Pekmezian, A., & Cobb,W. (2024). Antithyroid drug-induced hepatotoxicity from chronic use. Journal of the Endocrine Society, 8(3), 85–90.
8. Danan, G., & Benichou,C. (1993). Causalityassessment of adversereactions to drugs —I. A novel method based on the conclusions of international consensus meetings. Journal of Clinical Epidemiology, 46(11), 1323–1330.
9. Rockey, D. C.,Seeff, L. B., Rochon, J., et al. (2010). Causality assessment in drug-induced liver injury using a structured expert opinion process. Hepatology, 51(6), 2117–2126.
10. Abid, S., Jafri, W., Hamid, S., etal. (2005). Hepatotoxicity of antithyroid drugs.Journal of Pakistan Medical Association, 55(12), 523–526.
11. Jadallah, K. A., Limauro,D. L., & Coleppio, J. (2009). Carbimazole-induced cholestatic hepatitis in Graves' disease. Endocrine Abstracts, 19, P348.
12. Bartalena, L., Baldeschi, L., Boboridis, K., et al. (2016). The 2016 European Thyroid Association/European Group on Graves' Orbitopathy guidelines for the management of Graves' orbitopathy. European Thyroid Journal, 5(1), 9–26.
13. Hayashi, P. H., Rockey,D. C., Fontana, R. J., et al. (2027). Death and liver transplantation within2 years of onset of drug-induced liver injury. Hepatology, 66(4), 1275–1285.
14. Khan, A. A., Ata, F., Aziz,A., et al. (2024). Clinical characteristics and outcomes of patients with antithyroid drug–related liver injury. Journal of the Endocrine Society, 8(1), Article bvad133.
15. Zhu, X., & Chen, Y. (2025).Subacute liver failurecaused by hyperthyroidism complicated by drugs: A case report and review of the literature. Frontiers in Medicine.